Abstract:Lung cancer is the leading cause of cancer related death around the world. The last decade has witnessed the rapid development of epidermal growth factor receptor (EGFR) directly targeted therapies that have significantly changed the treatment of non–small cell lung cancer (NSCLC). However, the challenge of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) has been an issue when talking with activating EGFR mutations, which makes it crucial to elucidate the mechanism of EGFR-TKI targeted drug resistance. Methyl-sensitive cut counting sequencing (MSCC), one of the most commonly used whole-genome DNA methylation sequencing technology, was applied to investigate the changes of paired tissue DNA methylation before and after TKI (erlotinib) treatment lasting two cycles with partial response (PR) for stage IIIa (N2) lung adenocarcinoma patients (N=2) with activating EGFR 19 deletion. Sequenom EpiTYPER assay method was further analyzed to double confirm the changed methylated candidate genes in these two patients, through comparing the methylated changes in paired tissues before and after TKI treatment. Western blotting, cell cycle and apoptosis analysis by the up/down regulation of a candidate gene (GABBR2) were performed in three lung adenocarcinoma cell lines, A549 (EGFR wild type), HCC4006 (EGFR 19 deletion, DelL747-E749) and HCC827 (EGFR 19 deletion, DelE746-A750), to elucidate the mechanism of GABBR2 gene in the regulation of EGFR-TKI treatment. Sixty aberrant methylated genes were firstly discovered using MSCC method in these two patients harboring EGFR 19 del mutation treated with erlotinib. Two aberrant methylated genes, CBFA2T3 and GABBR2, were clearly validated by the Sequenom EpiTYPER assay subsequently. GABBR2 was significantly down regulated in HCC4006 and HCC827 cells harboring EGFR 19 mutations but remained conservative in A549 cells with EGFR wild-type after erlotinib treatment by Western blotting. The phenomenon was in line with the obvious apoptosis of HCC4006 and HCC827 cell lines after erlotinib treatment, but not in A549 cells. GABBR2 was further induced down regulation after erlotinib exposure through apoptosis method silenced by siRNA using RNAi technology. Meanwhile, GABBR2 gene was demonstrated up regulation rescued the apoptosis significantly, when overexpressing GABBR2 in HCC827 cell lines along with erlotinib treatment. Genome-wide screen of DNA methylation changes demonstrated that GABBR2 gene might be as a novel potential treatment target for stage IIIa (N2) EGFR 19 deletion adenocarcinoma with erlotinib treatment. Our research provides a new theoretical basis for the epigenetic study of EGFR mutated lung adenocarcinoma treatment.

Table S3 from Genome-wide DNA Methylation Analysis Reveals GABBR2 As a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment

Table S1 from Genome-wide DNA Methylation Analysis Reveals <i>GABBR2</i> as a Novel Epigenetic Target for <i>EGFR</i> 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment

Genome-Wide Dna Methylation Analysis Reveals Gabbr2 As A Novel Epigenetic Target for Egfr 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment

P3.02b-041 Genome-Wide Screen of DNA Methylation Changes Reveals GABBR2 As a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib: Topic: EGFR Biomarkers

PS01.80: Genome-Wide Screen of DNA Methylation Changes Reveals GABBR2 As a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib: Topic: Medical Oncology.

Genome-wide Screen of DNA Methylation Study in Stage IIIa (N2) EGFR 19 Deletion Adenocarcinoma with Erlotinib Treatment.

Genome-Wide Methylation Profiling of lncRNAs Reveals a Novel Progression-Related and Prognostic Marker for Colorectal Cancer

Genome-wide Methylation Profiling Reveals Differentially Methylated Genes in Blood DNA of Small-Cell Lung Cancer Patients

A Novel Acquired EGFR-SEPT14 Fusion Confers Differential Drug Resistance to EGFR Inhibitors in Lung Adenocarcinoma.

Expression, DNA methylation pattern and transcription factor EPB41L3 in gastric cancer: a study of 262 cases

Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression

Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer

Ctdna SNORD3F Hypermethylation is a Prognostic Indicator in EGFR-TKI-Treated Advanced Non-Small Cell Lung Cancer

An integrated epigenomic-transcriptomic landscape of lung cancer reveals novel methylation driver genes of diagnostic and therapeutic relevance

Aberrant m5C hypermethylation mediates intrinsic resistance to gefitinib through NSUN2/YBX1/QSOX1 axis in EGFR-mutant non-small-cell lung cancer

Abstract 1611: DNA methylation co-operates with genomic alterations during non-small cell lung cancer evolution

Identification of Tissue-Specific Gene Clusters Induced by DNA Demethylation in Lung Adenocarcinoma: More Than Germline Genes

Hypermethylated Epidermal growth factor receptor (EGFR) promoter is associated with gastric cancer.

EGLN2 DNA Methylation and Expression Interact with HIF1A to Affect Survival of Early-Stage NSCLC

Identification of a novel gene signature of lung adenocarcinoma based on epidermal growth factor receptor-tyrosine kinase inhibitor resistance

Abstract 1679: Genome-wide Methylation Analysis in Barrett's Esophagus and Esophageal Adenocarcinoma